News Headlines Article

Cancer treatment maker BioCold Genesys lands $22M in funds
Los Angeles Business Journal

Cold Genesys Inc., a biopharmaceutical company developing novel immunotherapies used to treat cancer, has closed on $22 million in financing.

The Santa Ana, California-based company said the series C round was in the form of preferred stock. New investors participated in the round, including lead investor ORI Healthcare Fund L.P., with participation from Perseverance Capital Management.